PhageTech Company

The Company is developing a new generation of sensors that can will diseases such as cancer and infectious diseases in their earliest stages accurately, conveniently and instantaneously at low cost allowing accessibility to the physician or consumer even in developing countries, enabling early treatment saving millions of lives worldwide. The Company is participating in the lucrative $70B global in Vitro Diagnostics Market. This disruptive platform technology will radically change the current standard of diagnostics; the use of antibodies, that was introduced 40-50 years ago but are expensive, require controlled storage conditions and complicated sample workup limiting their usage worldwide. Alternatively PhageTech's sensors will be low cost, provide instant results, be convenient (used directly with any bodily fluid), and are highly sensitive and selective for disease biomarkers; even several at a time.
Technology: Biomarkers
Industry: Health Care, Medical, Medical Device
Headquarters: Irvine, California, United States
Founded Date: 2014-01-01
Employees Number: 1-10
Funding Status: Early Stage Venture
Investors Number: 3
Total Funding: $2.4M
Estimated Revenue: $1M to $10M
Last Funding Type: Series A

Visit Website
Register and Claim Ownership